WO2002076500A1 - Vaccine for the treatment of tubercolosis and other intracellular infections diseases - Google Patents
Vaccine for the treatment of tubercolosis and other intracellular infections diseases Download PDFInfo
- Publication number
- WO2002076500A1 WO2002076500A1 PCT/IN2001/000047 IN0100047W WO02076500A1 WO 2002076500 A1 WO2002076500 A1 WO 2002076500A1 IN 0100047 W IN0100047 W IN 0100047W WO 02076500 A1 WO02076500 A1 WO 02076500A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- tuberculosis
- cells
- macrophages
- allogeneic
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 83
- 230000003834 intracellular effect Effects 0.000 title claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 9
- 208000015181 infectious disease Diseases 0.000 title description 17
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 95
- 244000052769 pathogen Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000008569 process Effects 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 241000607142 Salmonella Species 0.000 claims abstract description 16
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 15
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 8
- 210000002540 macrophage Anatomy 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 59
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 241000699670 Mus sp. Species 0.000 claims description 30
- 230000000735 allogeneic effect Effects 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 22
- 210000004072 lung Anatomy 0.000 claims description 19
- 230000001681 protective effect Effects 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 17
- 210000004185 liver Anatomy 0.000 claims description 17
- 210000000952 spleen Anatomy 0.000 claims description 17
- 230000036039 immunity Effects 0.000 claims description 14
- 238000012544 monitoring process Methods 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 12
- 210000004241 Th2 cell Anatomy 0.000 claims description 11
- 230000035755 proliferation Effects 0.000 claims description 11
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 8
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 8
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 230000024932 T cell mediated immunity Effects 0.000 claims description 7
- 229960003350 isoniazid Drugs 0.000 claims description 7
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 7
- 241000222722 Leishmania <genus> Species 0.000 claims description 6
- 241000186362 Mycobacterium leprae Species 0.000 claims description 6
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 claims description 6
- 241000223104 Trypanosoma Species 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 229960002109 tuberculosis vaccine Drugs 0.000 claims description 6
- 241000589562 Brucella Species 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229960004857 mitomycin Drugs 0.000 claims description 5
- 241000224016 Plasmodium Species 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 claims description 3
- 230000002349 favourable effect Effects 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 39
- 210000004443 dendritic cell Anatomy 0.000 description 33
- 241000186359 Mycobacterium Species 0.000 description 23
- 102100037850 Interferon gamma Human genes 0.000 description 18
- 108010074328 Interferon-gamma Proteins 0.000 description 18
- 102000000588 Interleukin-2 Human genes 0.000 description 16
- 108010002350 Interleukin-2 Proteins 0.000 description 16
- 102000013462 Interleukin-12 Human genes 0.000 description 12
- 108010065805 Interleukin-12 Proteins 0.000 description 12
- 210000000612 antigen-presenting cell Anatomy 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 230000001640 apoptogenic effect Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 241000304886 Bacilli Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000008520 organization Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 206010024229 Leprosy Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000000680 phagosome Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000004554 Leishmaniasis Diseases 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000010907 stover Substances 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010006049 Bovine Tuberculosis Diseases 0.000 description 2
- 206010006500 Brucellosis Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000002311 trypanosomiasis Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 241000766754 Agra Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 201000006836 Miliary Tuberculosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- -1 TFN-γ Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000032922 susceptibility to mycobacterium tuberculosis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens.
- This vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.
- the utility of the present invention is to develop a vaccine against the intracellular pathogens, which are causative agent of tuberculosis, brucellosis, leishmaniasis, anceriosis, leprosy, malaria, typhoid, trypanosomiasis and streptococcus and HTV- infection.
- the pathogen Mycobacterium tuberculosis (M. tuberculosis) the subject matter of this invention is a causative agent of tuberculosis.
- M. tuberculosis was allowed to grow in the allogeneic and syngeneic macrophages and macrophage cell lines.
- the macrophages- tuberculosis complex was then irradiated to kill the macrcphag ⁇ s as well as the mycobacterium.
- Tuberculosis is a chronic infectious disease that continues to kill some 3 million people a year. About 8 million new cases arise every year and the number continues to increase. About one-third of the world population is infected with M. tuberculosis. The emergence of AIDS has reactivated tuberculosis in millions of dormant individuals, causing a sharp rise in the number of cases and deaths. M. tuberculosis is therefore responsible for the highest morbidity rate among all infectious agents. The only available vaccine BCG is both unpredictable and highly variable. Doubtful efficacy of BCG vaccination has put the scientific community to urgently develop effective means of vaccination against the M. tuberculosis (Bloom, B.R. et. al., Annu. Rev. Immunol. 10:1992:453).
- BCG has been extensively used as a vaccine world over.
- Several hundred million children and new born have been the recipient of BCG vaccine.
- tuberculosis has still become the fastest spreading disease not only in developing countries but also in the industrialized world.
- the protective efficacy of the current BCG vaccine is both unpredictable and highly variable and it remains the most controversial of all currently used vaccines. Its doubtful efficacy in controlled trials have increased the concern about its use as a vaccine (Bloom and Fine, Tuberculosis In B. Bloom (ed.), 1994:531, Bloom, B.R. et. al., Annu. Rev. Immunol. 10:1992:453).
- BCG's performance is based on a hypothesis that BCG is effective against primary infection in children and endogenous reactivation of long-standing infections but not against exogenous infection (ten Dam, H.G. Adv. Tuberc. Res. 21:1984:79; ten Dam, H.G. and A. Pio. Tubercle 63:1988:226).
- Epidemiological data suggest that BCG vaccination imparts greater or more consistent protection against systemic disease, in particular miliary tuberculosis and tuberculosis meningitis in children, than against pulmonary disease (Rodrigues, et.al., it J epidemiol. 22:1993:1154). Lurie's studies indicated that the number of CFU of M. tuberculosis isolated from lungs of BCG-immunized versus unimmunized rabbits showed no difference in the number of organisms reaching and capable of being cultured from lung and other tissues.
- MHC Major Histocompatibility Complex
- the effective resistance to M. tuberculosis infection will require participation both of specific CD8 CTL to lyse macrophages or parenchymal cells unable to restrict their infection and of specific CD4 + T cells able to produce IL-2, TFN- ⁇ , TNF- ⁇ , and other lymphokines involved in macrophage activation.
- specific CD8 CTL to lyse macrophages or parenchymal cells unable to restrict their infection and of specific CD4 + T cells able to produce IL-2, TFN- ⁇ , TNF- ⁇ , and other lymphokines involved in macrophage activation.
- the applicants have taken advantage of the fact that the vaccine will be used as an irradiated preparation and has no fear of inoculating in AIDS patients and immunocompromised children.
- BCG is given as an attenuated preparation and is not recommended in these subjects because it causes disseminated BCG-osis.
- Another insight is provided by the intracellular location of the mycobacterium.
- BCG remains essentially entirely within the phagolysosome of macrophages, whereas virulent M. tuberculosis can escape from the phagolysosome and enter the cytoplasm (McDonough, K.A., Y. Kress, and B.R. Bloom. 1993. Infect. Immun. 61:2763-2773).
- the antigens in the endosomal compartment of antigen-presenting cells are presented in conjunction with MHC class II determinants to CD4 + T helper cells, whereas cytoplasmic antigens are presented in association with the Major Histocompatibility Complex (MHC) class 1 determinants to CD8 + Cytotoxic T cells.
- MHC Major Histocompatibility Complex
- tuberculosis is more dependent for its elimination on MHC class I-restricted CTL.
- BCG is not effective in eliciting MHC class I- restricted CTL (Stover, et.al., Nature 351:1991:456).
- the present vaccine contains the irradiated preparation of M. tuberculosis grown in macrophages. M. tuberculosis infected macrophages are reported to effectively generate CTL (Stover, et.al., Nature 351:1991:456).
- irradiated cells undergo apoptosis and can be phagocytosed by the dendritic cells (Albert, M ., et.al., Nature 392:1998:86) and it leads to the generation of antigen specific CD4 + and CD8 + T cell response.
- This apoptosis-dependent pathway may not only have potential in vaccination studies but also for therapeutically manipulating immune system to induce T-helper and CTL response in vivo to a variety of antigens including tumor, and possibly to modulate favourable immune response.
- tuberculosis grown in the natural environment of the macrophages that secrete the unique antigens responsible for the induction of protective immune response and can generate CD4 + T-helper cells and CD8 + CTL.
- the effective resistance to M. tuberculosis infection will require participation of both specific CD8 CTL to lyse macrophages or parenchymal cells unable to restrict their infection and of specific CD4 + T cells able to produce IL-2, IFN- ⁇ , TNF- ⁇ , and other lymphokines involved in macrophage activation.
- Allo-macrophages in the system generate allo-reaction as a result large amount of cytokines like IL-2, IL-12, IFN- ⁇ , etc., are produced which promote the Thl response and cell mediated immune response. It is known that Thl -type of response provides protection against tuberculosis. Hence the main utility of the process was to produce a potent and specific vaccine against M. tuberculosis.
- the main object of the present invention thus is to develop a vaccine against tuberculosis and other intracellular diseases like leprosy, leishmaniasis, typhoid, trypanosomiasis, malaria, brucellosis, anceriosis, AIDS, streptococcal infection and cancer.
- Another object of the present invention is to culture the pathogen inside the syngeneic and allogeneic macrophages and allow them to secrete antigens within the cells. Yet another object is to develop a method whereby the pathogen are killed by the already known drugs and further will be gamma irradiated before use; the gamma irradiated cells are known to undergo apoptosis and are engulfed by the dendritic cells. Dendritic cells are potent activator of Thl cells and CD8+ cytotoxic cells.
- Still another objective of the present invention is to develop a vaccine based on entrapment of pathogen in the allogeneic cells that would elicit immune response irrespective of the genetic background i.e. it will work as a promiscuous vaccine, and hence it will work irrespective of the genetic diversity in the human subjects.
- the present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens.
- This vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.
- the novelty in the present invention is that the protective antigens secreted by the mycobacterium inside the macrophages can be used as a vaccine without isolating them from the macrophages.
- the vaccine was used after irradiation and the irradiated cells are known to undergo apoptosis.
- the cells undergoing apoptosis were engulfed by the dendritic cells.
- Dendritic cells activated na ⁇ ve T cell to differentiate into Thl cells and cytotoxic cells.
- the cells known to be cardinal in imparting protective immunity against intracellular infections and cancer.
- the allogeneic cells used in the construction of vaccine would elicit immune response irrespective of the genetic background i.e. it will work as a promiscuous vaccine. Hence it can used in human subjects irrespective of the genetic diversity.
- the aim of the present invention is to develop a vaccine against tuberculosis, salmonella and other intracellular infections.
- M. tuberculosis and Salmonella typhimurium was cultivated in allogeneic (AMTV) and syngeneic (SMTV) macrophages and was killed by ⁇ -irradiation and was used as a vaccine.
- the AMTV in vivo will preferably be engulfed by dendritic cells ( ⁇ -irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells) and will then activate the m y cobacterium reactive na ⁇ ve T cells.
- Allogeneic macrophages being used for immunization worked as an adjuvant and elicited allogeneic reactive T cells that produced huge amount of IL-2, IFN- ⁇ , IL-12. These cytokines are vital for the growth and differentiation of na ⁇ ve T cells to CD4 + and CD8 + effector T cells.
- Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL).
- Thl and CD8 + CTL are principal cells in generating effective and protective immunity against M. tuberculosis. The tuberculosis resistant and susceptible strains of mice were inoculated with the vaccine.
- FIG 1 represents schematically the process of how Allo-Macrophage Tuberculosis (AMTV) works.
- AMTV Allo-Macrophage Tuberculosis
- Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL). They cause stimulation of na ⁇ ve T cells to differentiate into antigen reactive Thl cells and cytotoxic T lymphocytes. Moreover, dendritic cells trap foreign antigen (in this case mycobacterium antigen) and act as a reservoir, slowly releasing the antigen in the system for the activation of T cells and for the maintenance of memory cells.
- APC Antigen Presenting Cells
- CTL cytotoxic T cells
- IL-2, IFN- ⁇ and IL-12 secreted by alloreactive T cells will engineer the clonal expansion of mycobacterium reactive Thl and cytotoxic T cells.
- Thl and CD8 + CTL are cardinal in generating effective and protective immunity against M. tuberculosis.
- the tuberculosis resistant and susceptible strains of mice were inoculated with the vaccine.
- the rationale behind the process of how Allo-Macrophage Tuberculosis (AMTV) works has been demonstrated by cultivating M. tuberculosis cultivating in MHC-mismatched (allogeneic) and syngeneic macrophages. This preparation was ⁇ -irradiated ana used as vaccine.
- the AMTV in vivo will preferably be engulfed by dendritic cells (as it is known that ⁇ -irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells) and will then activate the mycobacterium reactive na ⁇ ve T cells.
- dendritic cells as it is known that ⁇ -irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells
- macrophages loaded with mycobacterium cannot activate na ⁇ ve T cells directly. Allo- macrophages being used for immunization will elicit allo-reactive T cells that produce huge amount of IL-2, IFN- ⁇ , IL-12.
- cytokines are vital for the growth and differentiation of na ⁇ ve T cells to CD4 + and CD8 + effector T cells.
- Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL). They cause stimulation of na ⁇ ve T cells to differentiate into antigen reactive Thl cells and cytotoxic T lymphocytes. Moreover, dendritic cells trap foreign antigen (in this case mycobacterium antigen) and act as a reservoir, slowly releasing the antigen in the system for the activation of T cells and for the maintenance of memory cells. IL-2, IFN- ⁇ and IL-12 secreted by alloreactive T cells will engineer the clonal expansion of mycobacterium reactive Thl and cytotoxic T cells. Thl and CTL are cardinal in generating effective and protective immunity against M.
- APC Antigen Presenting Cells
- CTL cytotoxic T cells
- tuberculosis (Albert, M ., et. al., Nature 392:1998:86; Wang, B. et. al., Proc. Natl. Acad. Sci. USA 90:1993:4156).
- the tuberculosis resistant and susceptible strains of mice were vaccinated with AMTV and SMTV.
- the efficacy of the vaccine was monitored by infecting the mice with live M. tuberculosis and monitoring their mortality and viable counts of the bacteria in the lungs, spleen and liver.
- the vaccinated (4-12 weeks) mice were challenged with 10 5 -10 6 viable M. tuberculosis H37Rv.
- the lungs, spleens and livers of the infected mice were removed after an additional period of 3-4 weeks and serial dilutions of organ homogenate was plated on agar plates to establish the number of viable tubercle bacilli residing in these organs.
- the vaccinated animals were also monitored for the generation of Thl and Th2 cells by measuring IFN- ⁇ and IL-4.
- the vaccine was inoculated in the mouse footpad and the induction of delayed type hypersensitivity reaction was monitored by measuring the thickness of the footpa ⁇ .
- tuberculosis vaccine comprise M. tuberculosis cultivated in MHC- matched and mismatched-macrophages.
- the preparations are irradiated and used as distinct vaccines.
- the vaccine fulfill all the requirements necessary for generating favourable immune response against M. tuberculosis, it has been anticipated that such preparations should work effectively against tuberculosis.
- the vaccine AMTV works in a promiscuous manner, since it does not follow the rules of MHC-restriction and is based on allo-stimulation and engulfment of foreign-apoptotic cells by dendritic cells. Whereas the vaccine SMTV works in MHC-restriction fashion.
- the infected cells were grown in sufficient quantity and stored after isoniazid treatment and ⁇ -irradiation. The preparation was thoroughly checked for viable mycobacterium by viability counting. None of the bacteria were viable in the vaccine.
- the mice were vaccinated intraperitoneally or subcutaneously with vaccine and were challenged with viable M. tuberculosis H37Rv. The viability of the tubercle bacilli residing in lungs, spleens and livers was monitored. The animals were immunized with the vaccine and the uptake of the apoptotic cells by dendritic cells was documented by immuno fluorescence.
- the animals were vaccinated with SMTV and AMTV and the proliferation and differentiation of na ⁇ ve CD4 + Th cells into effector Thl and Th2 subtype was studied.
- M. tuberculosis entrapped in syngeneic macrophages was also used.
- the ability of SMTV and AMTV to generate CD8 + cytotoxic T cells was monitored by the standard Cr 51 - release assay.
- mice were immunized with ovalbumin entrapped in mitomycin C treated allogeneic and syngeneic APC.
- IA k CBA mice
- Antigen-specific-T cell proliferation and predominant Thl response were noticed, as evidenced by mainly the production of IL- 2 and IFN- ⁇ and IgG2a-isotype.
- High production of IL-2 in allo-response was noticed which indicates that the immunization with the antigen entrapped in allo-APC treated with mitomycin C undergoes apoptosis.
- the apoptotic cells are engulfed by dendritic cells that then evokes mycobacterium specific and the allo-reactive T cells response.
- the allo-T cells are >10% of the total T cell population and are known to induce high secretion of IL-2.
- IL- 2 produced by allo-T cells then engineers the proliferation of antigen specific T cell.
- M. tuberculosis was cultivated in the macrophage cell line viz. J77.4 or allogeneic and syngeneic macrophages.
- the infected macrophages were isoniazid treated and irradiated and then used for vaccination studies in protection against M. tuberculosis.
- Allo-Macrophage Tuberculosis (AMTV) works has been demonstrated by cultivating M. tuberculosis cultivating in MHC-mismatched (allogeneic) and syngeneic macrophages. This preparation was ⁇ -irradiated and used as vaccine.
- the AMTV in vivo will preferably be engulfed by dendritic cells (as it is known that ⁇ -irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells) and will then activate the mycobacterium reactive na ⁇ ve T cells.
- dendritic cells as it is known that ⁇ -irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells
- macrophages loaded with mycobacterium cannot activate na ⁇ ve T cells directly. Allo- macrophages being used for immunization will elicit allo-reactive T cells that produce huge amount of IL-2, IFN- ⁇ , IL-12.
- cytokines are vital for the growth and differentiation of na ⁇ ve T cells to CD4 + and CD8 + effector T cells.
- Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL). They cause stimulation of na ⁇ ve T cells to differentiate into antigen reactive Thl cells and cytotoxic T lymphocytes. Moreover, dendritic cells trap foreign antigen (in this case mycobacterium antigen) and act as a reservoir, slowly releasing the antigen in the system for the activation of T cells and for the maintenance of memory cells. IL-2, IFN- ⁇ and IL-12 secreted by alloreactive T cells will engineer the clonal expansion of mycobacterium reactive Thl and cytotoxic T cells. Thl and CTL are cardinal in generating effective and protective immunity against M.
- APC Antigen Presenting Cells
- CTL cytotoxic T cells
- tuberculosis (Albert, MX., et. al., Nature 392:1998:86; Wang, B. et. al., Proc. Natl. Acad. Sci. USA 90:1993:4156).
- the tuberculosis resistant and susceptible strains of mice were vaccinated with AMTV and SMTV.
- the efficacy of the vaccine was monitored by infecting the mice with live M. tuberculosis and monitoring their mortality and viable counts of the bacteria in the lungs, spleen and liver.
- the vaccinated (4-12 weeks) mice were challenged with 10 5 -10 6 viable M. tuberculosis H37Rv.
- the lungs, spleens and livers of the infected mice were removed after an additional period of 3-4 weeks and serial dilutions of organ homogenate was plated on agar plates to establish the number of viable tubercle bacilli residing in these organs.
- the vaccinated animals were also monitored for the generation of Thl and Th2 cells by measuring IFN- ⁇ and IL-4.
- the vaccine was inoculated in the mouse footpad and the induction of delayed type hypersensitivity reaction was monitored by measuring the thickness of the footpad.
- the present invention provides a vaccine against tuberculosis and other intracellular pathogens selected from the group consisting of Mycobacterium leprae, leishmania, salmonella, trypanosoma, plasmodium, brucella, leisteria, HIV, streptococc s and cancer.
- the invention also provides a mthod for the development of the said vaccine, comprising the steps of: i) culturing pathogens selected from the group comprising Mycobacterium tuberculosis, Mycobacterium leprae, leishmania, salmonella, trypanosoma, plasmodium, brucella, leisteria, HIV, streptococcas ii) culturing syngeneic (same strain), allogeneic (different strain) and xenogeneic (different species like sheep and goat) macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines with a pathogen, iv) treating the infected cells with known drugs followed by gamma irradiation to obtain the vaccine, v) immunizing disease resistant and susceptible strains of animals with the vaccine obtained above.
- pathogens selected from
- the invention further provides a process for the preparation of a vaccine against tuberculosis, wherein the said process comprising the steps of: i) culturing of Mycobacterium tuberculosis H37Rv, ii) culturing of syngeneic and allogeneic macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines (J774, P388D1, RAW, BMC-2, THP-1) with M.
- tuberculosis iv) treating the infected cells with isoniazid and gamma irradiation to obtain the vaccine, v) immunizing tuberculosis resistant and susceptible strains of mice with allogeneic macrophage tuberculosis vaccine (AMTV) and syngeneic macrophage tuberculosis vaccine (SMTV) obtained above, vi) infecting the mice with live M.
- AMTV allogeneic macrophage tuberculosis vaccine
- SMTV syngeneic macrophage tuberculosis vaccine
- tuberculosis and monitoring their mortality and viable counts of bacteria in lungs, spleen and liver
- the invention also provides a process for the preparation of a vaccine against salmonella, wherein the said process comprising the steps of: i) culturing of. Salmonella typhimurium, ii) culturing of syngeneic and allogeneic macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines (J774, P388D1, RAW, BMC-2, THP-1) with
- S. typhimurium iv) treating the infected cells with mitomycin C and gamma irradiation to obtain vaccine, v) immunizing tuberculosis resistant and susceptible strains of mice with vaccine obtained above, vi) infecting the mice with live S. typhimurium and monitoring their mortality and viable counts of bacteria in lungs, spleen and liver, vii) monitoring the vaccinated animals for proliferation and generation of CD4 + Thl and Th2 cells and CD8 + cytotoxic T cells indicating the generation of cell mediated immunity, and viii) inoculating the vaccine in the mouse footpad and examining the delayed type hypersensitivity reaction by measuring the swelling in the footpad for protective immunity.
- the invention provides a vaccine by entrapment of M. tuberculosis, Salmonella and other intracellular pathogens in the allogeneic and syngeneic macrophages and using it for the protection against the infectious agent.
- Examplel A process for the preparation of a vaccine against tuberculosis End other intracellular pathogens.
- the intracellular pathogens viz. Mycobacterium tuberculosis, Mycobacterium leprae, leishmania, salmonella, trypanosoma, p.' modiu , brucella, leisteria, HIV, streptococcas were cultured in the macrophages of syngeneic and allogeneic mice, macrophages cell lines J774, P338D1, RAW, BMC-2, THP-1 (ATCC, Rockville). The infected cells were treated with isoniazid (20 ⁇ g/ml) for 48h at 37°C/5% CO 2 and irradiated at 0.05 kGy. i.
- Example2 A process for the preparation of a vaccine against tuberculosis.
- Mycobacterium tuberculosis H37Rv obtained from Central JALMA Institute for Leprosy, Agra, was cultured in the macrophages of syngeneic and allogeneic mice, macrophages cell lines J774, P338D1, RAW, BMC-2, THP-1 (ATCC, Rockville). The infected cells were treated with isoniazid (20 ⁇ g/ml) for 48h at 37 °C/5% CO 2 and irradiated at 0.05 kGy. i.
- Example3 A process for the preparation of a vaccine against salmonella.
- Salmonella typhimurium (MTCC98) was cultured in the macrophages obtained from syngeneic and allogeneic mice and macrophages cell lines J774, BMC-2 and RAW.
- the infected cells were treated with mitomycin C (50 ⁇ g/ml) and gamma irradiated (0.05 kGy).
- mitomycin C 50 ⁇ g/ml
- gamma irradiated 0.05 kGy
- the resultant infected cells were treated with the drug and irradiated and were used as a vaccine and their efficacy was monitored by challenging the vaccinated mice with 10 5 - 10 6 viable bacteria. The animals were observed for mortality for 21 days.
- the lungs, spleens and livers of the infected mice were removed and serial dilutions of organ homogenates was plated on agar plates to establish the number of viable salmonella bacilli residing in these organs.
- the unvaccinated animals were challenged with live bacteria and were monitored for their mortality and viable counts in lungs, spleens and livers.
- M. tuberculosis (i) About one-third of the world population is infected with M. tuberculosis. About 5-10% only develop active tuberculosis and the 90% of the individual develop effective immunity against the M. tuberculosis. M. tuberculosis present in the host macrophages secretes unique antigens, which are the effective inducers of long lasting protective immunity. In contrast, M. tuberculosis when cultured in vitro in artificial medium, secrete antigens that do not induce optimum level of protection and the immunity generated is short lived. The outstanding feature in the process is that the protective antigens of mycobacterium secreted inside the macrophages were utilized without isolating them from the macrophages.
- the advantage of the invention is that the ⁇ -irradiated mycobacterium infected macrophages were engulfed by dendritic cells.
- the ⁇ -irradiated cells are known to undergo apoptosis.
- Apoptotic cells taken up by the dendritic cells induce the activation of CD4 Thl and CD8 + cytotoxic T cells.
- Cytotoxic T cells are responsible for the killing of macrophages infected with mycobacterium. Lysis of target is essential in the case of diseases like tuberculosis, typhoid, leprosy, leishmaniasis, AIDS, etc., where the pathogen reside and multiplies within the macrophages.
- Dendritic cells express high level of B7-1 and secrete IL-12 and are only potent APC that can activate na ⁇ ve T cells. Moreover, dendritic cells can differentiate na ⁇ ve T cells to Thl and CD8 + cytotoxic T cells. Thl and cytotoxic T cells are vital for induction of protective immunity against tuberculosis (Wakeham, et. al., J. Immunol., 160:1998:6101).
- dendrites on dendritic cells trap the foreign antigens and work as a reservoir. This antigen is slowly released from the dendrites, and is responsible for the maintenance of memory cells.
- the AMTV vaccine works in MHC-unrestricted manner, because it is based on allo- stimulation and engulfment of apoptotic cells by dendritic cells. It will work for all human, irrespective of the genetic diversity.
Abstract
The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens, this vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.
Description
VACCINE FOR THE TREATMENT OF TUBERCOLOSIS AND OTHER INTRACELLULAR INFECTIONS
DISEASES
Technical Field
The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens. This vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.
The utility of the present invention is to develop a vaccine against the intracellular pathogens, which are causative agent of tuberculosis, brucellosis, leishmaniasis, leisteriosis, leprosy, malaria, typhoid, trypanosomiasis and streptococcus and HTV- infection. The pathogen Mycobacterium tuberculosis (M. tuberculosis) the subject matter of this invention is a causative agent of tuberculosis. In this invention M. tuberculosis was allowed to grow in the allogeneic and syngeneic macrophages and macrophage cell lines. The macrophages- tuberculosis complex was then irradiated to kill the macrcphagεs as well as the mycobacterium.
Background Art Tuberculosis is a chronic infectious disease that continues to kill some 3 million people a year. About 8 million new cases arise every year and the number continues to increase. About one-third of the world population is infected with M. tuberculosis. The emergence of AIDS has reactivated tuberculosis in millions of dormant individuals, causing a sharp rise in the number of cases and deaths. M. tuberculosis is therefore responsible for the highest morbidity rate among all infectious agents. The only available vaccine BCG is both unpredictable and highly variable. Doubtful efficacy of BCG vaccination has put the scientific community to urgently develop effective means of vaccination against the M. tuberculosis (Bloom, B.R. et. al., Annu. Rev. Immunol. 10:1992:453).
During the past many decades BCG has been extensively used as a vaccine world over. Several hundred million children and new born have been the recipient of BCG vaccine. However, in spite of wide usage of BCG vaccine, tuberculosis has still become the fastest spreading disease not only in developing countries but also in the industrialized world. Further, the protective efficacy of the current BCG vaccine is both unpredictable and highly variable and it remains the most controversial of all currently used vaccines. Its
doubtful efficacy in controlled trials have increased the concern about its use as a vaccine (Bloom and Fine, Tuberculosis In B. Bloom (ed.), 1994:531, Bloom, B.R. et. al., Annu. Rev. Immunol. 10:1992:453). Furthermore, the extensive clinical trials done in Madras showed similar extent of protection in BCG-vaccinated and unvaccinated individuals, indicating that BCG induced zero protection (Ind. J. Med. Res. 1980:72(Suppl.):l-74). Thus it is obvious that BCG vaccination does not prevent transmission.
In past also, many questions always arose pertaining to the safe use of BCG vaccine:
A major catastrophe that cast a cloud over the reputation of BCG vaccination occurred in 1929. hi Lubeck, Germany, 251 children received a BCG vaccine prepared at a local institute, and 72 of these children died. Subsequent investigation revealed that the institute also maintained cultures of virulent tubercle bacilli and that the batch of BCG vaccine given to the children had accidentally been contaminated with one of these strains of Mycobacterium tuberculosis (Lubeck. 1935. Die Sauglingstuberkulose in Lubeck. Springer, Berlin). A new question has arisen regarding the safety of BCG in HlV-infected individuals. A small number of cases of disseminated BCG-osis have been reported among children who received BCG vaccine and were subsequently found to be HIV seropositive (Von Reyn, et. al. Lancet 1987: ii:669-672; Braun, et. al, Pediatr. Infect. Dis. J. 1992:11:220-227; eltman, et. al., AIDS 7:1993:149). WHO currently recommends discontinuing the use of BCG vaccine in children showing over signs of immunodeficiency (Worid Health Organization. 1992. Expanded Program for Immunization. Program Report. World Health Organization, Geneva. World Health Organization. Weekly Epidemiol. Rec. 62:1987:53).
Large volunteers studies by Dahlstrom and Difts (Scand J Respir Dis Suppl. 65:1968:35) and a meta-analysis of BCG in the prevention of tuberculosis based on 13 prospective studies and 10 case control studies has recently been completed (Colditz et. al., J. Amer. Med. Assoc. 271:1994:698-702). While it concluded that on average BCG was about 50% protective in preventing tuberculosis, the biological and operational significance of averaging, in essence, such widely divergent results are itself arguable.
Before the advent of AIDS, in most wealthy countries, the incidence of tuberculosis was declining for at least a century. This is illustrated in comparisons between The Netherlands (which never employed BCG vaccination) and the United Kingdom and Scandinavia (which instituted national BCG vaccination in the 1950). The declines in tuberculosis cases reported in these countries were similar (Sfr' lo, K., Selected Papers R. Netherland Tuberc.
Assoc. 24:1991:136; Sutherland, Bull. Int. Union. 57:1981:17). Thus it is unreasonable to attribute that the decline was due to BCG vaccination alone.
BCG's performance is based on a hypothesis that BCG is effective against primary infection in children and endogenous reactivation of long-standing infections but not against exogenous infection (ten Dam, H.G. Adv. Tuberc. Res. 21:1984:79; ten Dam, H.G. and A. Pio. Tubercle 63:1988:226). Epidemiological data suggest that BCG vaccination imparts greater or more consistent protection against systemic disease, in particular miliary tuberculosis and tuberculosis meningitis in children, than against pulmonary disease (Rodrigues, et.al., it J epidemiol. 22:1993:1154). Lurie's studies indicated that the number of CFU of M. tuberculosis isolated from lungs of BCG-immunized versus unimmunized rabbits showed no difference in the number of organisms reaching and capable of being cultured from lung and other tissues.
Another insight is provided by the intracellular location of the mycobacterium. Electron microscopic findings indicate that BCG remains essentially entirely within the phagolysosomes after in vitro infection of macrophages, whereas virulent M. tuberculosis (strain H37Rv) can escape from the phagolysosome and enter the cytoplasm (McDonough, et.al., Infect. Immun. 61:1993:2763). This may be relevant insofar as it is the antigens in the endosomal compartment of antigen-presenting cells that are presented in conjunction with MHC class II determinants to CD4 T helper cells, whereas cytoplasmic antigens are presented in association with the Major Histocompatibility Complex (MHC) class I determinants to CD8+ Cytotoxic T cells (CTL). If these findings in vitro are general, they will explain why M. tuberculosis is more dependent for its elimination on MHC class I- restricted CTL than BCG and suggests that BCG may not be very effective in eliciting MHC class I-restricted CTL (Stover, et.al, Nature 351:1991:456). h this context, Rich, 1951 (The Pathogenesis of Tuberculosis, 2nd, 1028p. Charles C Thomas, Publisher, Springfield, III), Canetti, 1955 (The Tubercule Bacilli in the Pulmonary Lesion of Man, 226p. Springer, New York.) and Lurie, 1964 (Resistance to Tuberculosis. Experimental Studies in Native and Acquired Defense, 39 lp. Harvard University Press, Cambridge Press, Cambridge, Mass), commented that recovery from infection with M. tuberculosis provided stronger protection against future tuberculosis than could BCG.
The effective resistance to M. tuberculosis infection will require participation both of specific CD8 CTL to lyse macrophages or parenchymal cells unable to restrict their infection and of specific CD4+ T cells able to produce IL-2, TFN-γ, TNF-α, and other lymphokines involved in macrophage activation.
Considering these drawbacks of the BCG-vaccine, the applicants have taken advantage of the fact that the vaccine will be used as an irradiated preparation and has no fear of inoculating in AIDS patients and immunocompromised children. BCG is given as an attenuated preparation and is not recommended in these subjects because it causes disseminated BCG-osis. WHO currently recommends discontinuing the use of BCG vaccine in children showing overt signs of immunodeficiency (World Health Organization. 1992. Expanded Program for Immunization. Program Report. World Health Organization, Geneva. World Health Organization. Weekly Epidemiol. Rec. 1987:62:53-54).
Another insight is provided by the intracellular location of the mycobacterium. BCG remains essentially entirely within the phagolysosome of macrophages, whereas virulent M. tuberculosis can escape from the phagolysosome and enter the cytoplasm (McDonough, K.A., Y. Kress, and B.R. Bloom. 1993. Infect. Immun. 61:2763-2773). The antigens in the endosomal compartment of antigen-presenting cells are presented in conjunction with MHC class II determinants to CD4+ T helper cells, whereas cytoplasmic antigens are presented in association with the Major Histocompatibility Complex (MHC) class 1 determinants to CD8+ Cytotoxic T cells. M. tuberculosis is more dependent for its elimination on MHC class I-restricted CTL. BCG is not effective in eliciting MHC class I- restricted CTL (Stover, et.al., Nature 351:1991:456). The present vaccine contains the irradiated preparation of M. tuberculosis grown in macrophages. M. tuberculosis infected macrophages are reported to effectively generate CTL (Stover, et.al., Nature 351:1991:456). Further, it has also been reported that irradiated cells undergo apoptosis and can be phagocytosed by the dendritic cells (Albert, M ., et.al., Nature 392:1998:86) and it leads to the generation of antigen specific CD4+ and CD8+ T cell response. This apoptosis-dependent pathway may not only have potential in vaccination studies but also for therapeutically manipulating immune system to induce T-helper and CTL response in vivo to a variety of antigens including tumor, and possibly to modulate favourable immune response.
Rich (The pathogenesis of Tuberculosis. 2nd ed, 1028p., 1951. Charles C Thomas, Publisher, Springfield, 111), Canetti (The tubercle Bacillus in the pulmonary Lesion of Man, 226p, 1955. Springer, New York), and Lurie (Resistance to Tuberculosis. Experimental Studies in Native and Acquired Defense, 391, 1964. Harvard University Press, Cambridge, Mass) have commented that recovery from infection with M. tuberculosis provided stronger protection against future tuberculosis than could BCG. In context with the above statements, the cand' late vaccine has advantage over existing BCG
vaccine because it contains the M. tuberculosis grown in the natural environment of the macrophages that secrete the unique antigens responsible for the induction of protective immune response and can generate CD4+ T-helper cells and CD8+ CTL. The effective resistance to M. tuberculosis infection will require participation of both specific CD8 CTL to lyse macrophages or parenchymal cells unable to restrict their infection and of specific CD4+ T cells able to produce IL-2, IFN-γ, TNF-α, and other lymphokines involved in macrophage activation.
The main rationale behind this process was to develop a vaccine against tuberculosis other intracellular diseases, MHC-matched (syngeneic) and mismatched (allogeneic) macrophages harboring M. tuberculosis on irradiation undergo apoptosis; dendritic cells engulf these macrophages and present the antigen (Mycobacterium-proteins and allo- macrophage peptides) on their surface and induce naϊve T-cells to differentiate into effecter CD4+ Thl cells. These dendritic cells also activate CD8+ T cells for cell-mediated immunity. Allo-macrophages in the system generate allo-reaction as a result large amount of cytokines like IL-2, IL-12, IFN-γ, etc., are produced which promote the Thl response and cell mediated immune response. It is known that Thl -type of response provides protection against tuberculosis. Hence the main utility of the process was to produce a potent and specific vaccine against M. tuberculosis.
Objects of the invention The main object of the present invention thus is to develop a vaccine against tuberculosis and other intracellular diseases like leprosy, leishmaniasis, typhoid, trypanosomiasis, malaria, brucellosis, leisteriosis, AIDS, streptococcal infection and cancer.
Another object of the present invention is to culture the pathogen inside the syngeneic and allogeneic macrophages and allow them to secrete antigens within the cells. Yet another object is to develop a method whereby the pathogen are killed by the already known drugs and further will be gamma irradiated before use; the gamma irradiated cells are known to undergo apoptosis and are engulfed by the dendritic cells. Dendritic cells are potent activator of Thl cells and CD8+ cytotoxic cells.
Another object is to develop a vaccine that acts against both syngeneic macrophages entrapped pathogens (viz. M. tuberculosis, M. leprae, leishmania, salmonella, trypanosoma, malaria, bracella, leisteria, HIV, streptococcas) (e.g. SMTV, S=syngeneic,
M=macrophage, T=tuberculosis, V=vaccine) and allogeneic-macrophages entrapped
pathogen vaccine (eg. AMTV, A=allo, M=macrophage, T=tuberculosis, V=vaccine), to generate protective immune response.
Still another objective of the present invention is to develop a vaccine based on entrapment of pathogen in the allogeneic cells that would elicit immune response irrespective of the genetic background i.e. it will work as a promiscuous vaccine, and hence it will work irrespective of the genetic diversity in the human subjects.
Summary of the Invention:
The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens. This vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.
Detailed Description of the invention
The novelty in the present invention is that the protective antigens secreted by the mycobacterium inside the macrophages can be used as a vaccine without isolating them from the macrophages.
The vaccine was used after irradiation and the irradiated cells are known to undergo apoptosis. The cells undergoing apoptosis were engulfed by the dendritic cells. Dendritic cells activated naϊve T cell to differentiate into Thl cells and cytotoxic cells. The cells known to be cardinal in imparting protective immunity against intracellular infections and cancer.
Allo-macrophages in the system generated allo-reaction as a result large amount of cytokines like IL-2, IL-12, IFN-γ, etc., are produced which promote the Thl response and cell mediated immune response. The allogeneic cells used in the construction of vaccine would elicit immune response irrespective of the genetic background i.e. it will work as a promiscuous vaccine. Hence it can used in human subjects irrespective of the genetic diversity.
The aim of the present invention is to develop a vaccine against tuberculosis, salmonella and other intracellular infections. M. tuberculosis and Salmonella typhimurium was cultivated in allogeneic (AMTV) and syngeneic (SMTV) macrophages and was killed by γ-irradiation and was used as a vaccine. The AMTV in vivo will preferably be engulfed by dendritic cells (γ-irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells) and will then activate the mycobacterium reactive naϊve T cells. Allogeneic
macrophages being used for immunization worked as an adjuvant and elicited allogeneic reactive T cells that produced huge amount of IL-2, IFN-γ, IL-12. These cytokines are vital for the growth and differentiation of naϊve T cells to CD4+ and CD8+ effector T cells. Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL). Thl and CD8+ CTL are principal cells in generating effective and protective immunity against M. tuberculosis. The tuberculosis resistant and susceptible strains of mice were inoculated with the vaccine.
Description of the accompanying drawings
Figure 1 represents schematically the process of how Allo-Macrophage Tuberculosis (AMTV) works.
The rationale behind the process of how Allo-Macrophage Tuberculosis (AMTV) works has been schematically shown in figure 1. M. tuberculosis was cultivated in MHC- mismatched (allogeneic) and syngeneic macrophages. This preparation was γ-irradiated and used as vaccine. The AMTV in vivo will preferably be engulfed by dendritic cells (as it is known that γ-irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells) and will then activate the mycobacterium reactive naϊve T cells. However, macrophages loaded with mycobacterium cannot activate naϊve T cells directly. Allogeneic macrophages being used for immunization would elicit allogeneic reactive T cells that produce huge amount of IL-2, IFN-γ, IL-12. These cytokines are vital for the growth and differentiation of naϊve T cells to CD4+ and CD8+ effector T cells. Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL). They cause stimulation of naϊve T cells to differentiate into antigen reactive Thl cells and cytotoxic T lymphocytes. Moreover, dendritic cells trap foreign antigen (in this case mycobacterium antigen) and act as a reservoir, slowly releasing the antigen in the system for the activation of T cells and for the maintenance of memory cells. IL-2, IFN-γ and IL-12 secreted by alloreactive T cells will engineer the clonal expansion of mycobacterium reactive Thl and cytotoxic T cells. Thl and CD8+ CTL are cardinal in generating effective and protective immunity against M. tuberculosis. The tuberculosis resistant and susceptible strains of mice were inoculated with the vaccine. The rationale behind the process of how Allo-Macrophage Tuberculosis (AMTV) works has been demonstrated by cultivating M. tuberculosis cultivating in MHC-mismatched (allogeneic) and syngeneic macrophages. This preparation was γ-irradiated ana used as vaccine. The AMTV in vivo will preferably be engulfed by dendritic cells (as it is known
that γ-irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells) and will then activate the mycobacterium reactive naϊve T cells. However, macrophages loaded with mycobacterium cannot activate naϊve T cells directly. Allo- macrophages being used for immunization will elicit allo-reactive T cells that produce huge amount of IL-2, IFN-γ, IL-12. These cytokines are vital for the growth and differentiation of naϊve T cells to CD4+ and CD8+ effector T cells. Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL). They cause stimulation of naϊve T cells to differentiate into antigen reactive Thl cells and cytotoxic T lymphocytes. Moreover, dendritic cells trap foreign antigen (in this case mycobacterium antigen) and act as a reservoir, slowly releasing the antigen in the system for the activation of T cells and for the maintenance of memory cells. IL-2, IFN-γ and IL-12 secreted by alloreactive T cells will engineer the clonal expansion of mycobacterium reactive Thl and cytotoxic T cells. Thl and CTL are cardinal in generating effective and protective immunity against M. tuberculosis (Albert, M ., et. al., Nature 392:1998:86; Wang, B. et. al., Proc. Natl. Acad. Sci. USA 90:1993:4156). The tuberculosis resistant and susceptible strains of mice were vaccinated with AMTV and SMTV. The efficacy of the vaccine was monitored by infecting the mice with live M. tuberculosis and monitoring their mortality and viable counts of the bacteria in the lungs, spleen and liver. The vaccinated (4-12 weeks) mice were challenged with 105-106 viable M. tuberculosis H37Rv. The lungs, spleens and livers of the infected mice were removed after an additional period of 3-4 weeks and serial dilutions of organ homogenate was plated on agar plates to establish the number of viable tubercle bacilli residing in these organs. The vaccinated animals were also monitored for the generation of Thl and Th2 cells by measuring IFN-γ and IL-4. The vaccine was inoculated in the mouse footpad and the induction of delayed type hypersensitivity reaction was monitored by measuring the thickness of the footpaύ.
According to the present invention there is provided a novel vaccine against tuberculosis and other intracellular pathogens and a process for the development thereof. The tuberculosis vaccine (SMTV and AMTV), comprise M. tuberculosis cultivated in MHC- matched and mismatched-macrophages. The preparations are irradiated and used as distinct vaccines.
Since the vaccine fulfill all the requirements necessary for generating favourable immune response against M. tuberculosis, it has been anticipated that such preparations should work effectively against tuberculosis.
The vaccine AMTV works in a promiscuous manner, since it does not follow the rules of MHC-restriction and is based on allo-stimulation and engulfment of foreign-apoptotic cells by dendritic cells. Whereas the vaccine SMTV works in MHC-restriction fashion.
The infected cells were grown in sufficient quantity and stored after isoniazid treatment and γ-irradiation. The preparation was thoroughly checked for viable mycobacterium by viability counting. None of the bacteria were viable in the vaccine. The mice were vaccinated intraperitoneally or subcutaneously with vaccine and were challenged with viable M. tuberculosis H37Rv. The viability of the tubercle bacilli residing in lungs, spleens and livers was monitored. The animals were immunized with the vaccine and the uptake of the apoptotic cells by dendritic cells was documented by immuno fluorescence. The animals were vaccinated with SMTV and AMTV and the proliferation and differentiation of naϊve CD4+ Th cells into effector Thl and Th2 subtype was studied. As a control, M. tuberculosis entrapped in syngeneic macrophages was also used. The ability of SMTV and AMTV to generate CD8+ cytotoxic T cells was monitored by the standard Cr51- release assay.
To test the hypothesis of allo-stimulation, Balb/c (IAd) and C57BL/6 (IA ) strains of mice were immunized with ovalbumin entrapped in mitomycin C treated allogeneic and syngeneic APC. To eliminate the possibility of preferably generating allo-response in secondary response, the haplotype of the allo-APC was changed. The animals were given secondary booster with ovalbumin entrapped in the APC of CBA (IAk) mice. Profound activation of CD4+ and CD8+ T cells was observed. Antigen-specific-T cell proliferation and predominant Thl response were noticed, as evidenced by mainly the production of IL- 2 and IFN-γ and IgG2a-isotype. High production of IL-2 in allo-response was noticed which indicates that the immunization with the antigen entrapped in allo-APC treated with mitomycin C undergoes apoptosis. The apoptotic cells are engulfed by dendritic cells that then evokes mycobacterium specific and the allo-reactive T cells response. The allo-T cells are >10% of the total T cell population and are known to induce high secretion of IL-2. IL- 2 produced by allo-T cells then engineers the proliferation of antigen specific T cell.
Therefore, in the present invention the development of effective tuberculosis vaccine; based on a novel delivery system targeted to dendritic cells, M. tuberculosis was cultivated in the macrophage cell line viz. J77.4 or allogeneic and syngeneic macrophages. The infected macrophages were isoniazid treated and irradiated and then used for vaccination studies in protection against M. tuberculosis.
The rationale behind the process of how Allo-Macrophage Tuberculosis (AMTV) works has been demonstrated by cultivating M. tuberculosis cultivating in MHC-mismatched (allogeneic) and syngeneic macrophages. This preparation was γ-irradiated and used as vaccine. The AMTV in vivo will preferably be engulfed by dendritic cells (as it is known that γ-irradiation causes cells to undergo apoptosis and dendritic cells engulf apoptotic cells) and will then activate the mycobacterium reactive naϊve T cells. However, macrophages loaded with mycobacterium cannot activate naϊve T cells directly. Allo- macrophages being used for immunization will elicit allo-reactive T cells that produce huge amount of IL-2, IFN-γ, IL-12. These cytokines are vital for the growth and differentiation of naϊve T cells to CD4+ and CD8+ effector T cells. Dendritic cells are the preferred Antigen Presenting Cells (APC) for Thl and cytotoxic T cells (CTL). They cause stimulation of naϊve T cells to differentiate into antigen reactive Thl cells and cytotoxic T lymphocytes. Moreover, dendritic cells trap foreign antigen (in this case mycobacterium antigen) and act as a reservoir, slowly releasing the antigen in the system for the activation of T cells and for the maintenance of memory cells. IL-2, IFN-γ and IL-12 secreted by alloreactive T cells will engineer the clonal expansion of mycobacterium reactive Thl and cytotoxic T cells. Thl and CTL are cardinal in generating effective and protective immunity against M. tuberculosis (Albert, MX., et. al., Nature 392:1998:86; Wang, B. et. al., Proc. Natl. Acad. Sci. USA 90:1993:4156). The tuberculosis resistant and susceptible strains of mice were vaccinated with AMTV and SMTV. The efficacy of the vaccine was monitored by infecting the mice with live M. tuberculosis and monitoring their mortality and viable counts of the bacteria in the lungs, spleen and liver. The vaccinated (4-12 weeks) mice were challenged with 105-106 viable M. tuberculosis H37Rv. The lungs, spleens and livers of the infected mice were removed after an additional period of 3-4 weeks and serial dilutions of organ homogenate was plated on agar plates to establish the number of viable tubercle bacilli residing in these organs. The vaccinated animals were also monitored for the generation of Thl and Th2 cells by measuring IFN-γ and IL-4. The vaccine was inoculated in the mouse footpad and the induction of delayed type hypersensitivity reaction was monitored by measuring the thickness of the footpad. Accordingly, the present invention provides a vaccine against tuberculosis and other intracellular pathogens selected from the group consisting of Mycobacterium leprae, leishmania, salmonella, trypanosoma, plasmodium, brucella, leisteria, HIV, streptococc s and cancer. The invention also provides a mthod for the development of the said vaccine, comprising the steps of:
i) culturing pathogens selected from the group comprising Mycobacterium tuberculosis, Mycobacterium leprae, leishmania, salmonella, trypanosoma, plasmodium, brucella, leisteria, HIV, streptococcas ii) culturing syngeneic (same strain), allogeneic (different strain) and xenogeneic (different species like sheep and goat) macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines with a pathogen, iv) treating the infected cells with known drugs followed by gamma irradiation to obtain the vaccine, v) immunizing disease resistant and susceptible strains of animals with the vaccine obtained above. vi) infecting the animals with live pathogen and monitoring their mortality nά viable counts of infectious agent in lungs, spleen and liver, and vii) monitoring the vaccinated animals for proliferation and generation of CD4+ Thl and Th2 cells and CD8 cytotoxic T cells indicating the generation of cell mediated immunity.
The invention further provides a process for the preparation of a vaccine against tuberculosis, wherein the said process comprising the steps of: i) culturing of Mycobacterium tuberculosis H37Rv, ii) culturing of syngeneic and allogeneic macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines (J774, P388D1, RAW, BMC-2, THP-1) with M. tuberculosis, iv) treating the infected cells with isoniazid and gamma irradiation to obtain the vaccine, v) immunizing tuberculosis resistant and susceptible strains of mice with allogeneic macrophage tuberculosis vaccine (AMTV) and syngeneic macrophage tuberculosis vaccine (SMTV) obtained above, vi) infecting the mice with live M. tuberculosis and monitoring their mortality and viable counts of bacteria in lungs, spleen and liver,
vii) monitoring the vaccinated animals for proliferation and generation of CD4 Thl and Th2 cells and CD8+ cytotoxic T cells indicating the generation of cell mediated immunity, viii) inoculating the vaccine in the mouse footpad and examining the delayed type hypersensitivity reaction by measuring the swelling in the footpad for protective immunity.
The invention also provides a process for the preparation of a vaccine against salmonella, wherein the said process comprising the steps of: i) culturing of. Salmonella typhimurium, ii) culturing of syngeneic and allogeneic macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines (J774, P388D1, RAW, BMC-2, THP-1) with
S. typhimurium, iv) treating the infected cells with mitomycin C and gamma irradiation to obtain vaccine, v) immunizing tuberculosis resistant and susceptible strains of mice with vaccine obtained above, vi) infecting the mice with live S. typhimurium and monitoring their mortality and viable counts of bacteria in lungs, spleen and liver, vii) monitoring the vaccinated animals for proliferation and generation of CD4+ Thl and Th2 cells and CD8+ cytotoxic T cells indicating the generation of cell mediated immunity, and viii) inoculating the vaccine in the mouse footpad and examining the delayed type hypersensitivity reaction by measuring the swelling in the footpad for protective immunity.
The invention provides a vaccine by entrapment of M. tuberculosis, Salmonella and other intracellular pathogens in the allogeneic and syngeneic macrophages and using it for the protection against the infectious agent.
The process of the present invention is illustrated in the examples given below which should not, however, be constructed to limit the scope of the present invention.
Examplel: A process for the preparation of a vaccine against tuberculosis End other intracellular pathogens.
The intracellular pathogens viz. Mycobacterium tuberculosis, Mycobacterium leprae, leishmania, salmonella, trypanosoma, p.' modiu , brucella, leisteria, HIV, streptococcas
were cultured in the macrophages of syngeneic and allogeneic mice, macrophages cell lines J774, P338D1, RAW, BMC-2, THP-1 (ATCC, Rockville). The infected cells were treated with isoniazid (20 μg/ml) for 48h at 37°C/5% CO2 and irradiated at 0.05 kGy. i. (a) The resultant infected cells were treated with the pathogen specific drug and further irradiated and was used as a vaccine and their efficacy was monitored by challenging the vaccinated mice with the viable bacteria. The efficacy of the vaccine was monitored by counting the viability of the infectious organism in the lungs, spleens and livers of the infected mice by serial dilutions of organ homogenate plated on the agar plates after definite interval of time. Similarly, the unvaccinated animals were challenged with live bacteria and were monitored for their mortality and viable counts in lungs, spleens and livers.
(b) The vaccinated animals were monitored for proliferation and differentiation of CD4+ Th cell into bacteria reactive effector cytotoxic T cells, Thl and Th2 cells by measuring IFN-γ and IL-4 by ELISA. (c) CD8+ cytotoxic T cells were monitored by 51Cr-release assay.
Example2: A process for the preparation of a vaccine against tuberculosis. In another example, Mycobacterium tuberculosis H37Rv obtained from Central JALMA Institute for Leprosy, Agra, was cultured in the macrophages of syngeneic and allogeneic mice, macrophages cell lines J774, P338D1, RAW, BMC-2, THP-1 (ATCC, Rockville). The infected cells were treated with isoniazid (20 μg/ml) for 48h at 37 °C/5% CO2 and irradiated at 0.05 kGy. i. (a) The resultant infected cells were treated with isoniazid and then gamma irradiated to use as a vaccine and their efficacy was monitored by challenging the vaccinated mice with 105-106 viable bacteria, h this case the lungs, spleens and livers of the infected mice were removed after an additional period of 3-4 weeks and serial dilutions of organ homogenate was plated on agar plates to establish the number of viable M. tuberculosis residing in the these organs. Similarly, the unvaccinated animals were challenged with live bacteria and were monitored for their mortality and viable counts in lungs, spleens and livers.
(b) The vaccinated animals were monitored for proliferation and differentiation of T cells into bacteria reactive effector CD8+ cytotoxic T cells and CD4+ Thl and Th2 cells by measuring IFN-γ and IL-4 by ELISA.
(c) CD8+ cytotoxic T cells were monitored by 51Cr-release assay.
(d) The vaccine was inoculated in the mouse footpad and the delayed type hypersensitivity reaction was monitored by measuring the thickness of the footpad.
Example3: A process for the preparation of a vaccine against salmonella.
In another example, Salmonella typhimurium (MTCC98) was cultured in the macrophages obtained from syngeneic and allogeneic mice and macrophages cell lines J774, BMC-2 and RAW. The infected cells were treated with mitomycin C (50 μg/ml) and gamma irradiated (0.05 kGy). i.(a) The resultant infected cells were treated with the drug and irradiated and were used as a vaccine and their efficacy was monitored by challenging the vaccinated mice with 105- 106 viable bacteria. The animals were observed for mortality for 21 days. The lungs, spleens and livers of the infected mice were removed and serial dilutions of organ homogenates was plated on agar plates to establish the number of viable salmonella bacilli residing in these organs. Similarly, the unvaccinated animals were challenged with live bacteria and were monitored for their mortality and viable counts in lungs, spleens and livers.
(b) The vaccinated animals were monitored for proliferation and differentiation of CD4+ Th cell into bacteria reactive effector Thl and Th2 cells by measuring IFN-γ and IL-4 by
ELISA.
(c) CD8+ cytotoxic T cells were monitored by 51Cr-release assay.
(d) The vaccine was inoculated in the mouse footpad and the delayed type hypersensitivity reaction was monitored by measuring the thickness of the footpad. Advantages:
The main advantages of the present invention are:-
(i) About one-third of the world population is infected with M. tuberculosis. About 5-10% only develop active tuberculosis and the 90% of the individual develop effective immunity against the M. tuberculosis. M. tuberculosis present in the host macrophages secretes unique antigens, which are the effective inducers of long lasting protective immunity. In contrast, M. tuberculosis when cultured in vitro in artificial medium, secrete antigens that do not induce optimum level of protection and the immunity generated is short lived. The outstanding feature in the process is that the protective antigens of mycobacterium secreted inside the macrophages were utilized without isolating them from the macrophages. (ii) These allo-macrophages used in the system functions as a unique system for delivering antigens secreted by live mycobacterium to dendritic cells and as an adjuvant for eliciting the secretion of cytokines viz. IL-2, IL-12, IFN-γ, etc., from allo-reactive T cells. The
excess of IL-2 secreted was utilized by the mycobacterium reactive protective T cells. Therefore there was no need for any adjuvant to be used. Alloreactive T cells produce chiefly IL-2, IFN-γ and IL-12, the cytokines responsible for the generation of Thl -like immune response. Thl are crucial for inducing protective immunity against M. tuberculosis.
(iii) The advantage of the invention is that the γ-irradiated mycobacterium infected macrophages were engulfed by dendritic cells. The γ-irradiated cells are known to undergo apoptosis. Apoptotic cells taken up by the dendritic cells induce the activation of CD4 Thl and CD8+ cytotoxic T cells. Cytotoxic T cells are responsible for the killing of macrophages infected with mycobacterium. Lysis of target is essential in the case of diseases like tuberculosis, typhoid, leprosy, leishmaniasis, AIDS, etc., where the pathogen reside and multiplies within the macrophages. Lysis of these cells liberates the pathogen and gives an opportunity to activated macrophages to engulf the bacteria and eliminate it. Dendritic cells express high level of B7-1 and secrete IL-12 and are only potent APC that can activate naϊve T cells. Moreover, dendritic cells can differentiate naϊve T cells to Thl and CD8+ cytotoxic T cells. Thl and cytotoxic T cells are vital for induction of protective immunity against tuberculosis (Wakeham, et. al., J. Immunol., 160:1998:6101).
(iv) Another advantage and uniqueness in the invention is that the dendrites on dendritic cells trap the foreign antigens and work as a reservoir. This antigen is slowly released from the dendrites, and is responsible for the maintenance of memory cells.
(v) The AMTV vaccine works in MHC-unrestricted manner, because it is based on allo- stimulation and engulfment of apoptotic cells by dendritic cells. It will work for all human, irrespective of the genetic diversity.
Claims
1. A process for the preparation of a vaccine against tuberculosis and other intracellular pathogens selected from the group consisting of Mycobacterium leprae, leishmania, salmonella, trypanosoma, plasmodium, brucella, leisteria, HIV, streptococcas and cancer wherein the said process comprising the steps of: i) culturing pathogens selected from the group comprising of Mycobacterium tuberculosis, Mycobacterium leprae, leishmania, salmonella, trypanosoma, plasmodium, brucella, leisteria, HIV, streptococcas ii) culturing syngeneic (same strain), allogeneic (different strain) and xenogeneic (different species like sheep and goat) macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines with a pathogen, iv) treating the infected cells with known drugs followed by gamma irradiation to obtain the vaccine, v) immunizing disease resistant and susceptible strains of animals with the vaccine obtained above, vi) infecting the animals with live pathogen and monitoring their mortality and viable counts of infectious agent in lungs, spleen and liver, and vii) monitoring the vaccinated animals for proliferation and generation of CD4+ Thl and Th2 cells and CD8+ cytotoxic T cells indicating the generation of cell mediated immunity.
2. A process for the preparation of a vaccine against tuberculosis, said process comprising the steps of: i) culturing Mycobacterium tuberculosis H37Rv, ii) culturing syngeneic and allogeneic macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines (J774, P388D1, RAW, BMC-2, THP-1) with M. tuberculosis, iv) treating the infected cells with isoniazid and gamma irradiation to obtain the vaccine, v) immunizing tuberculosis resistant and susceptible strains of mice with allogeneic macrophage tuberculosis vaccine (AMTV) and syngeneic macrophage tuberculosis vaccine (SMTV) obtained above, vi) infecting the mice with live M. tuberculosis and monitoring their mortality and viable counts of bacteria in lungs, spleen and liver, vii) monitoring the vaccinated animals for proliferation and generation of CD4+ Thl and Th2 cells and CD8+ cytotoxic T cells indicating the generation of cell mediated immunity, and viii) inoculating the vaccine in the mouse footpad and examining the delayed type hypersensitivity reaction by measuring the swelling in the footpad for protective immunity.
3. A process for the preparation of a vaccine against salmonella, said process comprising the steps of:
i) culturing Salmonella typhimurium, ϋ) culturing syngeneic and allogeneic macrophages and macrophage cell lines selected from the group consisting of J774A, P388D1, RAW, BMC-2, THP-1, etc., iii) infecting macrophages and cell lines (J774, P388D1, RAW, BMC-2, THP-1) with S. typhimurium, iv) treating the infected cells with mitomycin C and gamma irradiation to obtain vaccine, v) immunizing tuberculosis resistant and susceptible strains of mice with vaccine obtained above, vi) infecting the mice with live S. typhimurium and monitoring their mortality and viable counts of bacteria in lungs, spleen and liver, vii) monitoring the vaccinated animals for proliferation and generation of CD4+ Thl and Th2 cells and CD8+ cytotoxic T cells indicating the generation of cell mediated immunity, and viii) inoculating the vaccine in the mouse footpad and examining the delayed type hypersensitivity reaction by measuring the swelling in the footpad for protective immunity.
. A process for the construction of a vaccine and for therapeutically manipulating immune system to induce T-helper and CTL response in vivo to a variety of antigens including tumor, and possibly to modulate favourable immune response substantially as herein described with reference to the examples.
5. A vaccine as prepared by the process as claimed in claim 1 wherein by entrapment of M. tuberculosis, Salmonella and other intracellular pathogens in the allogeneic and syngeneic macrophages. The preparations were treated by the available drugs against the pathogens. The vaccine would further be gamma irradiated before using for the protection against the infectious diseases and cancer.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR0107058-4A BR0107058A (en) | 2001-03-23 | 2001-03-23 | Process for preparing a vaccine for the treatment of tuberculosis and other intracellular diseases and infections and the vaccine produced by such a process |
| CNB01802209XA CN100496605C (en) | 2001-03-23 | 2001-03-23 | Vaccine for treatment of tubercolosis and other intracellular infections diseases and preparing process thereof |
| PCT/IN2001/000047 WO2002076500A1 (en) | 2001-03-23 | 2001-03-23 | Vaccine for the treatment of tubercolosis and other intracellular infections diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2001/000047 WO2002076500A1 (en) | 2001-03-23 | 2001-03-23 | Vaccine for the treatment of tubercolosis and other intracellular infections diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002076500A1 true WO2002076500A1 (en) | 2002-10-03 |
Family
ID=11076318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2001/000047 WO2002076500A1 (en) | 2001-03-23 | 2001-03-23 | Vaccine for the treatment of tubercolosis and other intracellular infections diseases |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN100496605C (en) |
| BR (1) | BR0107058A (en) |
| WO (1) | WO2002076500A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4146232A4 (en) * | 2020-05-04 | 2024-04-10 | Univ Yeditepe | Use of extracellular vesicles as immunoprophilactics and immunotherapeutics for leishmaniasis |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100354002C (en) * | 2005-05-31 | 2007-12-12 | 中国人民解放军第三军医大学第一附属医院 | New type of cell vaccine with heteroimmune cell as cell vector and its prepn process |
| CN108743931B (en) | 2018-05-02 | 2022-08-16 | 成都威斯克生物医药有限公司 | Vaccine against tuberculosis and its preparation method and use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4064007A (en) * | 1975-03-03 | 1977-12-20 | Institut National De La Sante Et De La Recherche Medicale | Process for obtaining an active product from mammalian macrophages |
| EP0223218A2 (en) * | 1985-11-22 | 1987-05-27 | Christiane Prof. Dr. Stang-Voss | Conditioned macrophages and process for their preparation |
-
2001
- 2001-03-23 WO PCT/IN2001/000047 patent/WO2002076500A1/en active Application Filing
- 2001-03-23 BR BR0107058-4A patent/BR0107058A/en not_active Application Discontinuation
- 2001-03-23 CN CNB01802209XA patent/CN100496605C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4064007A (en) * | 1975-03-03 | 1977-12-20 | Institut National De La Sante Et De La Recherche Medicale | Process for obtaining an active product from mammalian macrophages |
| EP0223218A2 (en) * | 1985-11-22 | 1987-05-27 | Christiane Prof. Dr. Stang-Voss | Conditioned macrophages and process for their preparation |
Non-Patent Citations (2)
| Title |
|---|
| DAS GOBARDHAN ET AL: "Leishmania donovani infection of a susceptible host results in apoptosis of Th1-like cells: Rescue of anti-leishmanial CMI by providing Th1-specific bystander costimulation.", MICROBIOLOGY AND IMMUNOLOGY, vol. 42, no. 11, 1998, pages 795 - 801, XP001011602, ISSN: 0385-5600 * |
| SILVA C L: "New vaccines against tuberculosis.", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 28, no. 8, August 1995 (1995-08-01), pages 843 - 851, XP001041555 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4146232A4 (en) * | 2020-05-04 | 2024-04-10 | Univ Yeditepe | Use of extracellular vesicles as immunoprophilactics and immunotherapeutics for leishmaniasis |
Also Published As
| Publication number | Publication date |
|---|---|
| BR0107058A (en) | 2005-02-15 |
| CN1420784A (en) | 2003-05-28 |
| CN100496605C (en) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gong et al. | The current status, challenges, and future developments of new tuberculosis vaccines | |
| Lozes et al. | Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex | |
| Zhan et al. | Differential activation of Brucella-reactive CD4+ T cells by Brucella infection or immunization with antigenic extracts | |
| Andersen | Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins | |
| Yingst et al. | T cell immunity to brucellosis | |
| Cayabyab et al. | Current and novel approaches to vaccine development against tuberculosis | |
| Skinner et al. | Vaccination of animals against Mycobacterium bovis | |
| US20090304750A1 (en) | Novel prime-boost combinations of attenuated mycobacterium | |
| JP2008521435A (en) | Mycobacterium electroporation and overexpression of antigens in mycobacteria | |
| US6783765B2 (en) | Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process | |
| Soleimanpour et al. | A century of attempts to develop an effective tuberculosis vaccine: Why they failed? | |
| Yi et al. | Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice | |
| JP2023153868A (en) | Compositions for use as prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients | |
| WO2002076500A1 (en) | Vaccine for the treatment of tubercolosis and other intracellular infections diseases | |
| EP2341928B1 (en) | Mycobacterium tuberculosis vaccine | |
| Roberts et al. | Expansion and retention of pulmonary CD4+ T cells after prime boost vaccination correlates with improved longevity and strength of immunity against tularemia | |
| Xu et al. | Evaluation of immunogenicity and protective efficacy elicited by Mycobacterium bovis BCG overexpressing Ag85A protein against Mycobacterium tuberculosis aerosol infection | |
| Hernandez-Pando et al. | Recombinant BCG vaccine candidates | |
| RU2262950C2 (en) | Method for obtaining vaccine for treating tuberculosis and other intracellular infectious diseases and vaccine obtained according to declared method | |
| US8481024B2 (en) | Vaccines against tularemia | |
| Sharma et al. | Potent role of vaccines prepared from macrophages infected with live bacteria in protection against Mycobacterium tuberculosis and Salmonella typhimurium infections | |
| US8163294B2 (en) | Growth regulatable recombinant BCG compositions | |
| Yu et al. | Polyethylenimine modified nanoparticle adjuvant increases therapeutic efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 in mice infected with Mycobacterium tuberculosis | |
| Balasubramanian et al. | Versatile use of Mycobacterium indicus pranii (MIP) vaccine | |
| ZA200306367B (en) | Immunomodulator for the management of human immunodeficiency virus (HIV) disease/infection. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 1200200297 Country of ref document: VN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 01802209X Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1372/DELNP/2003 Country of ref document: IN Ref document number: 01372/DELNP/2003 Country of ref document: IN |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |